Polydeoxyribonucleotide Promotes Longitudinal Bone Growth Through the Hepatic JAK2-STAT5/IGF-1 Axis Involving A2A Receptor Signaling
4 affiliations
- 1Department of Bio-Convergence System, Hoseo University, 20 Hoseo-ro, 79 Beon-gil, Baebang-eup, Asan 31499, Chungcheongnam-do, Republic of Korea
- 2Department of Food and Biotechnology, Graduate School, Hoseo University, Baebang-eup, Asan 31499, Chungcheongnam-do, Republic of Korea
- 3COSMAX NBT INC., Seongnam-si 13486, Gyeonggi-do, Republic of Korea
- 4Department of Biochemistry and Molecular Biology, Jeonbuk National University Medical School, 20 Geonji-ro, Deokjin-gu, Jeonju-si 54907, Jeollabuk-do, Republic of Korea
Abstract
Longitudinal bone growth is primarily regulated by the growth hormone (GH)-insulin-like growth factor-1 (IGF-1) axis. However, non-hormonal and orally administered strategies for promoting longitudinal growth remain limited. Here, we investigated the effects and mechanisms of polydeoxyribonucleotide (PDRN) on longitudinal bone growth in vitro and in vivo. In HepG2 cells, PDRN significantly increased IGF-1 mRNA expression and JAK2 and STAT5 phosphorylation without affecting cell viability. Pretreatment with ZM241385, a selective adenosine A2A receptor (A2AR) antagonist, significantly attenuated these responses, supporting the involvement of A2AR signaling. In mice, oral PDRN for 5 weeks significantly increased body length gain, growth plate thickness, and hepatic JAK2/STAT5 activation, elevating serum IGF-1 levels without altering GH levels or systemic toxicity markers. Quantitative micro-computed tomography analysis demonstrated improved trabecular and cortical bone microarchitecture with reduced porosity. Furthermore, PDRN modulated bone remodeling-related responses by suppressing lipopolysaccharide-induced osteoclastogenic marker expression in RAW 264.7 cells and enhancing osteogenic marker expression while downregulating RANKL in MC3T3-E1 cells. Overall, oral PDRN promotes longitudinal bone growth and improves microarchitecture via increased hepatic IGF-1 signaling and altered bone remodeling-related gene expression, supporting its potential as an oral candidate for skeletal growth.
Related
- Polydeoxyribonucleotide (PDRN) in Osteoarthritis: Immunomodulatory and Matrix-Supportive Potential, A2A Receptor-Associated Mechanisms, and Translational Challenges
- Andrographolide Promotes Post-Ischemic Endothelial Angiogenic Activity via IL-10-Mediated M2-Like Microglia-Endothelial Crosstalk Involving Endothelial VEGFR2 Upregulation.
- A novel 5-HT2A receptor-linked signalling pathway involving NAADP-mediated lysosomal Ca2+ release
- Insulin-like growth factor-1 receptor participates in the anti-MDS action involving the MICA/B-NKG2D axis
- Pregnane X receptor deletion induces a lean phenotype in chow-fed mice through a liver–ileum–muscle axis involving 6α-hydroxylated bile acids and Fgf15
BibTeX
@article{jeong2026polydeoxyribonucleotide,
title = {{Polydeoxyribonucleotide Promotes Longitudinal Bone Growth Through the Hepatic JAK2-STAT5/IGF-1 Axis Involving A2A Receptor Signaling}},
author = {Kyung-Min Jeong and Yu-Jin Choi and Seong-Been Yang and Minson Kweon and So-Young Rah and Hyun-Ja Jeong},
journal = {Molecules (Basel, Switzerland)},
year = {2026},
month = oct,
doi = {10.3390/molecules31193558},
url = {https://europepmc.org/article/PMC/PMC13666977},
note = {CC BY},
}
RIS
TY - JOUR
TI - Polydeoxyribonucleotide Promotes Longitudinal Bone Growth Through the Hepatic JAK2-STAT5/IGF-1 Axis Involving A2A Receptor Signaling
AU - Kyung-Min Jeong
AU - Yu-Jin Choi
AU - Seong-Been Yang
AU - Minson Kweon
AU - So-Young Rah
AU - Hyun-Ja Jeong
PY - 2026
DA - 2026/10/01
JO - Molecules (Basel, Switzerland)
DO - 10.3390/molecules31193558
UR - https://europepmc.org/article/PMC/PMC13666977
AB - Longitudinal bone growth is primarily regulated by the growth hormone (GH)-insulin-like growth factor-1 (IGF-1) axis. However, non-hormonal and orally administered strategies for promoting longitudinal growth remain limited. Here, we investigated the effects and mechanisms of polydeoxyribonucleotide (PDRN) on longitudinal bone growth in vitro and in vivo. In HepG2 cells, PDRN significantly increased IGF-1 mRNA expression and JAK2 and STAT5 phosphorylation without affecting cell viability. Pretreatment with ZM241385, a selective adenosine A2A receptor (A2AR) antagonist, significantly attenuated these responses, supporting the involvement of A2AR signaling. In mice, oral PDRN for 5 weeks significantly increased body length gain, growth plate thickness, and hepatic JAK2/STAT5 activation, elevating serum IGF-1 levels without altering GH levels or systemic toxicity markers. Quantitative micro-computed tomography analysis demonstrated improved trabecular and cortical bone microarchitecture with reduced porosity. Furthermore, PDRN modulated bone remodeling-related responses by suppressing lipopolysaccharide-induced osteoclastogenic marker expression in RAW 264.7 cells and enhancing osteogenic marker expression while downregulating RANKL in MC3T3-E1 cells. Overall, oral PDRN promotes longitudinal bone growth and improves microarchitecture via increased hepatic IGF-1 signaling and altered bone remodeling-related gene expression, supporting its potential as an oral candidate for skeletal growth.
SN - 1420-3049
ER -